Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

Daily Life, Monitoring, and Emergencies

At a Glance

ALSP progresses at different rates, so care centers on regular monitoring, fall prevention, swallowing safety, and advance planning. Sudden weakness, facial drooping, severe confusion, prolonged seizures, choking, or abrupt swallowing or alertness changes require emergency evaluation.

Living with ALSP means navigating a path that is both progressive and unpredictable. While the “average” disease duration is often cited in some studies as roughly 6.8 years, this figure is a statistical mean from specific groups and masks a vast range of experiences [1]. Some individuals face a rapid decline over a year or two, while others have lived with the condition for nearly 30 years [1].

For you and your caregivers, the focus shifts from the search for a diagnosis to the daily rhythms of monitoring, safety, and preparing for the unexpected.

The Rhythm of Progression

In many symptomatic patients, independence in activities of daily living—such as dressing, eating, and walking—can decline noticeably over a 24-month period once symptoms are established [2]. This decline is often mirrored by cerebral atrophy (shrinking of the brain) and increasing white matter damage seen on MRI [2][3].

  • Early-to-Mid Stages: Management focuses on maintaining mobility and safety. You may notice you need more time for tasks, develop a “shuffling” gait, or become more withdrawn (apathy) [4].
  • Late Stages: Care often becomes more intensive over time. Severe outcomes can include becoming bedridden, losing speech (aphasia), or requiring full assistance with all personal care and feeding [5][6]. While these are severe possibilities, they are not a guaranteed immediate timetable.

Emergency Red Flags and First Aid

While ALSP is a chronic condition, certain sudden symptoms are medical emergencies and should not automatically be attributed to ALSP.

  • Stroke-like Symptoms: Any sudden, one-sided weakness, facial drooping, or abrupt severe confusion should be treated as a possible stroke. Call your local emergency number (e.g., 911) immediately regardless of your ALSP diagnosis. These require immediate medical evaluation to rule out other treatable causes [7][8].
  • Seizures: These can occur particularly as the disease progresses [9]. If a seizure happens: time the seizure, protect the person from injury by clearing hazards, gently place them on their side when feasible, and do not restrain them or put anything in their mouth. Call emergency services for a first-time seizure, a seizure that lasts more than five minutes, or if the person does not fully wake up between repeated seizures [10].
  • Acute Deterioration and Choking: A sudden (over hours or days) change in alertness, fever, or an abrupt inability to swallow safely is an emergency [11][12]. This could signal an underlying infection (like a UTI or pneumonia) or a metabolic issue. Frequent coughing during meals or a “wet” sounding voice after drinking are signs of dysphagia (swallowing trouble) that put you at high risk for aspiration pneumonia [6][13]. Active choking or severe breathing difficulty requires immediate emergency medical attention.

Monitoring and Maintenance

Consistent monitoring helps you stay ahead of the disease. Your neurology team may use structured tools like the Montreal Cognitive Assessment (MoCA) (a brief thinking test) to track cognitive changes, and the Barthel Index to track physical independence [2][14]. These are optional; ensure your team considers how aphasia or motor stiffness might affect your scores.

  • Safety at Home: As gait worsens, falls become a major risk. A physical therapist can help you identify when it is time for a walker or a wheelchair and how to perform safe “transfers” to protect your caregivers’ backs [15].
  • Nutrition and Skin: In later stages, maintaining nutrition and preventing pressure sores (bedsores) becomes critical [6][16]. A dietitian and SLP can help coordinate nutritional plans safely.

Planning for the Future

Because the decline in ALSP can be steep, it is important to discuss “goals of care” early while you can fully participate in the conversation. This includes choosing a healthcare proxy (someone to make decisions if you cannot) and discussing preferences for feeding tubes and life-sustaining care [17].

Transitioning to palliative care—which focuses on comfort, symptom relief, and caregiver support—can provide an extra layer of support. Palliative care is not hospice; it can be introduced at any stage alongside standard neurology care to help align medical treatments with your personal goals [17][18].

Common questions in this guide

How quickly can ALSP progress?
ALSP progresses at very different rates. Some people decline over a year or two, while others have lived with the condition for nearly 30 years, so an average estimate cannot predict one person’s course.
Which changes in a person with ALSP require emergency help?
Call emergency services for sudden one-sided weakness, facial drooping, or abrupt severe confusion because these may be signs of a stroke or another treatable problem. Seek urgent help for a first seizure, a seizure lasting more than five minutes, repeated seizures without full recovery, active choking, severe breathing trouble, or a sudden inability to swallow safely. A sudden change in alertness with fever also needs prompt medical evaluation.
What should we do if someone with ALSP has a seizure?
Time the seizure, clear nearby hazards, and gently place the person on their side when feasible. Do not restrain them or put anything in their mouth; call emergency services for a first seizure, a seizure lasting longer than five minutes, or failure to wake fully between seizures.
How is daily function monitored in ALSP?
A neurology team may use the Montreal Cognitive Assessment, a brief thinking test, and the Barthel Index, which tracks physical independence in daily activities. Scores should be interpreted in context because aphasia, stiffness, or movement problems can make the results look different from the person’s usual abilities.
When can palliative care begin for someone with ALSP?
Palliative care can be added at any stage alongside regular neurology care. It focuses on comfort, symptom relief, caregiver support, and aligning treatment with the person’s goals; it is different from hospice.
How can we reduce falls and swallowing problems at home with ALSP?
A physical therapist can help choose mobility aids and teach safer transfers, while a speech-language pathologist and dietitian can help with swallowing and nutrition plans. Frequent coughing during meals or a wet-sounding voice after drinking should be reported because these signs can indicate swallowing trouble and aspiration risk.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often should we repeat functional assessments to establish an individualized baseline, recognizing that language or motor issues might affect the scores?
  2. 2.Can you help us develop a formal 'seizure action plan' so we know exactly what to do and when to call emergency services?
  3. 3.Who should we call first if we notice a gradual worsening of symptoms over a few days, compared to a sudden acute change?
  4. 4.Can we integrate palliative care services now to support our family's emotional and physical needs alongside our regular neurology care?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation.

    Konno T, Yoshida K, Mizuno T, et al.

    European journal of neurology 2017; (24(1)):37-45 doi:10.1111/ene.13125.

    PMID: 27680516
  2. 2

    Natural History of Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP): A Retrospective Patient Cohort Study.

    Hayer SN, McLaren DG, Nance RM, et al.

    Neurology and therapy 2026; (15(3)):1269-1292 doi:10.1007/s40120-026-00916-0.

    PMID: 41915097
  3. 3

    Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): Estimation of pathological lesion stage from brain images.

    Kinoshita M, Oyanagi K, Matsushima A, et al.

    Journal of the neurological sciences 2024; (461()):123027 doi:10.1016/j.jns.2024.123027.

    PMID: 38805875
  4. 4

    Cognitive dysfunction and symptoms of movement disorders in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

    Ikeuchi T, Mezaki N, Miura T

    Parkinsonism & related disorders 2018; (46 Suppl 1()):S39-S41 doi:10.1016/j.parkreldis.2017.08.018.

    PMID: 28827005
  5. 5

    A novel CSF-1R mutation in a family with hereditary diffuse leukoencephalopathy with axonal spheroids misdiagnosed as hydrocephalus.

    Wang M, Zhang X

    Neurogenetics 2019; (20(3)):155-160 doi:10.1007/s10048-019-00579-0.

    PMID: 31093799
  6. 6

    Biopsy histopathology in the diagnosis of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

    Mao C, Zhou L, Zhou L, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(2)):403-409 doi:10.1007/s10072-019-04116-7.

    PMID: 31705326
  7. 7

    Adult-onset diffuse leukoencephalopathy with axonal spheroids and pigmented glia presenting with acute stroke-like symptoms: A rare clinical scenario.

    Purohit B, Johandi F, Sitoh YY, et al.

    Radiology case reports 2020; (15(10)):1915-1920 doi:10.1016/j.radcr.2020.07.067.

    PMID: 32874384
  8. 8

    Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: Clinical and imaging characteristics.

    Makary MS, Awan U, Kisanuki YY, Slone HW

    The neuroradiology journal 2019; (32(2)):139-142 doi:10.1177/1971400918822136.

    PMID: 30614382
  9. 9

    Adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and Nasu-Hakola disease: lesion staging and dynamic changes of axons and microglial subsets.

    Oyanagi K, Kinoshita M, Suzuki-Kouyama E, et al.

    Brain pathology (Zurich, Switzerland) 2017; (27(6)):748-769 doi:10.1111/bpa.12443.

    PMID: 27608278
  10. 10

    Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia.

    Gelfand JM, Greenfield AL, Barkovich M, et al.

    Brain : a journal of neurology 2020; (143(2)):503-511 doi:10.1093/brain/awz390.

    PMID: 31840744
  11. 11

    A Novel Radiographic and Genetic Variant of Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Case Report.

    Nichol AA, Ngo AB, Alharthi M, et al.

    The Neurohospitalist 2026; (16(2)):197-203 doi:10.1177/19418744251377118.

    PMID: 40936738
  12. 12

    CSF1R-related leukoencephalopathy presenting with early apathy, hypoactivity, and cognitive flattening: a case report of a diagnostic challenge.

    Yang W, Li C, Zhang H, Zhang Y

    Frontiers in human neuroscience 2026; (20()):1702515 doi:10.3389/fnhum.2026.1702515.

    PMID: 41647755
  13. 13

    Clinical features and genetic characteristics of hereditary diffuse leukoencephalopathy with spheroids due to CSF1R mutation: a case report and literature review.

    Zhuang LP, Liu CY, Li YX, et al.

    Annals of translational medicine 2020; (8(1)):11 doi:10.21037/atm.2019.12.17.

    PMID: 32055602
  14. 14

    The ILLUMINATE natural history study in colony-stimulating factor 1 receptor-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

    Lynch DS, Wade C, Schöls L, et al.

    Brain communications 2026; (8(4)):fcag271 doi:10.1093/braincomms/fcag271.

    PMID: 42500553
  15. 15

    Common neuropathological features underlie distinct clinical presentations in three siblings with hereditary diffuse leukoencephalopathy with spheroids caused by CSF1R p.Arg782His.

    Robinson JL, Suh E, Wood EM, et al.

    Acta neuropathologica communications 2015; (3()):42 doi:10.1186/s40478-015-0219-x.

    PMID: 26141825
  16. 16

    Report of A Family with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Without Mutations in CSF1R, AARS1 or AARS2.

    Dulski J, Koga S, Dickson DW, Wszolek ZK

    Movement disorders clinical practice 2023; (10(2)):307-312 doi:10.1002/mdc3.13650.

    PMID: 36825047
  17. 17

    Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development.

    Papapetropoulos S, Pontius A, Finger E, et al.

    Frontiers in neurology 2021; (12()):788168 doi:10.3389/fneur.2021.788168.

    PMID: 35185751
  18. 18

    Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: developing a framework for improvements in care.

    Rutherford HA, Rush BK, Smith A, et al.

    Neurodegenerative disease management 2024; (14(5)):161-172 doi:10.1080/17582024.2024.2404378.

    PMID: 39363647

This page is for informational purposes only and does not constitute medical advice about ALSP. Your neurology team can tailor monitoring and care plans; call emergency services for sudden stroke-like symptoms, severe breathing trouble, or other urgent changes.

Get notified when new evidence is published on Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.